Changes in Serum Intact Fibroblast Growth Factor 23 Concentrations From Midlife to Late Life and Their Predictors in the Community: The ARIC Study

Junichi Ishigami; Yasuyuki Honda; Amy B Karger; Josef Coresh; Elizabeth Selvin; Pamela L Lutsey; Kunihiro Matsushita

doi:10.1016/j.mayocpiqo.2022.03.002

Changes in Serum Intact Fibroblast Growth Factor 23 Concentrations From Midlife to Late Life and Their Predictors in the Community: The ARIC Study

Mayo Clin Proc Innov Qual Outcomes. 2022 Apr 27;6(3):209-217. doi: 10.1016/j.mayocpiqo.2022.03.002. eCollection 2022 Jun.

Authors

Junichi Ishigami¹, Yasuyuki Honda¹, Amy B Karger², Josef Coresh¹, Elizabeth Selvin¹, Pamela L Lutsey³, Kunihiro Matsushita¹

Affiliations

¹ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
² Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis.
³ Division of Epidemiology and Community Health, University of Minnesota, Minneapolis.

Abstract

Objective: To investigate longitudinal changes in the blood concentration of fibroblast growth factor 23 (FGF23) from midlife to late life and their major predictors in the general population.

Patients and methods: In 14,444 participants of the Atherosclerosis Risk in Communities Study, we analyzed the association of 31,095 measurements of serum intact FGF23 with age using data from 3 visits (visit 2 [N=13,460; mean age, 57 years]; visit 3 [N=12,323; mean age, 60 years]; and visit 5 [N=6122; mean age, 76 years]) and a linear mixed-effects model. Among 5804 participants who had FGF23 measurements at both visits 3 and 5, we explored predictors of FGF23 change from midlife to late life using linear regression models. Prespecified risk factors were estimated glomerular filtration rate, body mass index, ever smoking, ever drinker, diabetes, hypertension, history of cardiovascular disease, total cholesterol, and high-density lipoprotein cholesterol.

Results: Median FGF23 concentrations were 41.9 pg/mL (interquartile interval [IQI], 33.9 to 51.8 pg/mL) at visit 2, 38.3 pg/mL (IQI, 30.6 to 48.3 pg/mL) at visit 3, and 55.0 pg/mL (IQI, 44.4 to 70.3 pg/mL) at visit 5. A linear mixed-effects model showed that the association of FGF23 with age was nonlinear, with a slight decline or no change in age 45-60 years and a monotonic increase in age greater than or equal to 65 years (FGF23, +10 to 15 pg/mL per 10 years of age). In a multivariable linear regression model, significantly greater increases in FGF23 were noted, with midlife estimated glomerular filtration rate less than 60 mL/min per 1.73 m² vs more than or equal to 60 mL/min per 1.73 m² (ΔFGF23, +4.4 pg/mL [95% CI, 0.9 to 8.0]), diabetes vs no diabetes (ΔFGF23, +6.2 pg/mL [95% CI, 4.1 to 8.3]), and hypertension vs no hypertension (ΔFGF23, +4.1 pg/mL [95% CI, 2.7 to 5.4]).

Conclusion: FGF23 did not show any major changes in midlife but increased linearly in late life. Reduced kidney function, diabetes, and hypertension were robustly associated with a greater increase in FGF23. Further investigations are needed to understand the potential mechanisms linking these conditions to an increase in FGF23 concentrations.

Keywords: ARIC, Atherosclerosis Risk in Communities; CVD, cardiovascular disease; FGF23, fibroblast growth factor 23; eGFR, estimated glomerular filtration rate.

Abstract

Grants and funding